Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

Drug Represents Potential New Approach for the Treatment of Inflammatory

Disease

Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline

MOUNTAIN VIEW, Calif., May 13 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor which is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of the first patient in this trial, ChemoCentryx will be entitled to receive a $10 million milestone payment from alliance partner GlaxoSmithKline (NYSE: GSK).

The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of CCX354 in healthy volunteers in single ascending dose and multiple ascending dose cohorts. Preclinical studies showed that the development candidate is a potent and selective antagonist of the CCR1 receptor without binding to other receptors, which might minimize off-target effects. The high potency and selectivity of the molecule is designed to provide a wider therapeutic window allowing continuous receptor coverage throughout the dosing regimen thought to be critical for efficacy.

The chemokine receptor CCR1 drives the recruitment of immune cells, such as monocytes and macrophages, associated with the inflammation underlying certain autoimmune diseases such as rheumatoid arthritis (RA), as well as other inflammatory diseases. Significant levels of CCR1 ligands, including a set of so-called "C6 super-activated ligands" (which are a result of enzymatic cleavage in the inflamed joints) have been shown to be present in synovial fluid from the joints
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TARRYTOWN, N.Y. , May 23, 2013 /PRNewswire/ ... reconstruction following mastectomy is an appropriate option ... mutations seeking to surgically reduce their breast cancer ... involves a gradual expansion process and a second ... of implants in the same surgery as mastectomy ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ... the development and commercialization of novel bile acid therapeutics ... cirrhosis, today announced that Mark Pruzanski ... at the Deutsche Bank Securities 38th Annual Health Care ... May 29, 2013 at 4:10 p.m. ET. ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... 3, 2011 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... $111.2 million, a 17 percent increase over revenues of ... Results for all periods of fiscal 2010 exclude ...
... IRVINE, Calif., Aug. 3, 2011 Endologix, Inc. ... of minimally invasive treatments for aortic disorders, announced ... Officer, is scheduled to present at two upcoming ... the 31st Annual Canaccord Genuity Growth Conference in ...
Cached Medicine Technology:Thoratec Reports Second Quarter Revenue Increase of 17 Percent 2Thoratec Reports Second Quarter Revenue Increase of 17 Percent 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 4Thoratec Reports Second Quarter Revenue Increase of 17 Percent 5Thoratec Reports Second Quarter Revenue Increase of 17 Percent 6Thoratec Reports Second Quarter Revenue Increase of 17 Percent 7Thoratec Reports Second Quarter Revenue Increase of 17 Percent 8Thoratec Reports Second Quarter Revenue Increase of 17 Percent 9Thoratec Reports Second Quarter Revenue Increase of 17 Percent 10Thoratec Reports Second Quarter Revenue Increase of 17 Percent 11Thoratec Reports Second Quarter Revenue Increase of 17 Percent 12Thoratec Reports Second Quarter Revenue Increase of 17 Percent 13Thoratec Reports Second Quarter Revenue Increase of 17 Percent 14Thoratec Reports Second Quarter Revenue Increase of 17 Percent 15Thoratec Reports Second Quarter Revenue Increase of 17 Percent 16Thoratec Reports Second Quarter Revenue Increase of 17 Percent 17Thoratec Reports Second Quarter Revenue Increase of 17 Percent 18Thoratec Reports Second Quarter Revenue Increase of 17 Percent 19Endologix to Present at Two Upcoming Conferences 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 HCG EZ Drops ... and is excited to announce it’s new weight loss initiative. “We ... we are offering our customers their money back if they don’t ... CEO of HCG EZ Drops. “The HCG Diet consists of ... the 21 pounds in 21 days.” , The controversial, cutting-edge diet ...
(Date:5/24/2013)... The leading retail brand Short Dresses ... prom dresses . Now that is quite unbelievable, especially in ... brand name since its origin. The retailer has already revealed ... this huge discount offer will be an added bonanza for ... privileged to announce that Short Dresses is to offer different ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Over the ... been gradually transforming, which has affected the Medical ... debt and seeking regular hours, more young physicians are ... or other medical groups,” says IBISWorld industry analyst Anna ... reimbursement pressure, a number of older physicians are selling ...
(Date:5/23/2013)... High blood glucose is associated with poor outcomes in ... to control hyperglycemia is a common practice in hospitals. ... benefit and even shows harms associated with the use ... (ACP) Clinical Guidelines Committee in a new evidence-based paper ... Medical Quality . , "Clinicians caring for hospitalized patients ...
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
Breaking Medicine News(10 mins):Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3
... The Journal of the American Dental Association ... in publishing a global theme issue on poverty ... the worlds biomedical publications., The Council of Science ... simultaneous publication by science journals throughout the world ...
... Medical Center may have solved the mystery surrounding the healing ... interest in gold salts as a treatment for rheumatoid arthritis ... gold salts in the early 1900s to ease the pain ... a high cost: The shots took months to take ...
... Sponsored by Health Improvement Institute, Consumer,Reports WebWatch, ... is organizing a one-day workshop Monday, November 12,to ... Internet., Held at the Hyatt Regency Hotel ... health experts, representatives of relevant,organizations, and consumers to ...
... Pre-Emption in Riegel v. Medtronic, Inc., WASHINGTON, Oct. ... Medical Technology Association,(AdvaMed) filed a joint amicus brief Friday ... v. Medtronic, Inc. arguing that the FDA should,continue to ... states that,no other legislative or regulatory entity is better ...
... J. Halamandaris,President of the National Association for Home Care ... the power of caring, both at home,and in their ... Hospice Month., "It is highly appropriate that we ... nurses, therapists, aides and other providers who have chosen,to ...
... publisher, is proud to be participating in a Global ... by the Council of Science Editors. , The CSE ... interest and debate on the crucial matters of poverty ... developed and developing countries will simultaneously publish papers on ...
Cached Medicine News:Health News:Journal of the American Dental Association spotlights poverty 2Health News:Scientists discover how gold eases pain of arthritis 2Health News:Can the Web Transform the U.S. Healthcare System? 2Health News:Can the Web Transform the U.S. Healthcare System? 3Health News:Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc. 2Health News:U.S. Celebrates National Home Care and Hospice Month in November 2Health News:9 SAGE journals participate in global theme issue on poverty and human development 2
... for the semi-quantitative determination of specific IgA ... results of the anti-Gliadin IgA assay can ... diagnosis of diseases associated with elevated levels ... of these autoantibodies are one indicator in ...
... The Urisys 1800 System is the proper ... urinalysis workload in a convenient and efficient ... designed for optimized work and data flow, ... terminal.Fast processing of test strips accelerates analysis ...
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Direct assays, no sample extraction, hydrolysis or other pretreatment required. Highly specific antiserum, minimal cross-reactivity with estrone, estradiol and other estrogen metabolites....
Medicine Products: